RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]

RR No. 25-2018: VAT Exemption on Diabetes, High Cholesterol, and Hypertension Medicines Starting January 1, 2019

RR No. 25-2018 exempts FDA-listed diabetes, cholesterol, and hypertension medicines from VAT on local sale starting January 1, 2019. Starting January 1, 2019, businesses selling covered medicines for diabetes, high cholesterol, and hypertension must treat qualified sales as VAT-exempt, but only if the drug or medicine is included in the official VAT-exempt list identified and […]